Skip to search formSkip to main contentSkip to account menu

casopitant

A centrally-acting neurokinin 1 (NK1) receptor antagonist with antidepressant and antiemetic activities. Casopitant competitively binds to and blocks… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (4)

AntiemeticsNeurokinin-1 Receptor AntagonistsPiperazinesPiperidines

Narrower (1)

GW679769
casopitant mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients
Casopitant is a potent and selective neurokinin‐1 receptor antagonist formerly under development for a number of indications… 
Review
2013
Review
2013
Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists
Abstract The difference in location between the receptor occupancy curve of an agonist and its functional response has been… 
2012
2012
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist
SummaryTwo studies were conducted in subjects with mild or moderate hepatic or renal impairment and subjects with normal organ… 
2011
2011
The potential role for corticosterone in the induction of cleft palate in mice after treatment with a selective NK-1 receptor antagonist, casopitant (GW679769B).
BACKGROUND Casopitant is a potent and selective NK-1 receptor antagonist that has shown clinical efficacy in the prevention of… 
2011
2011
NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs
The amino-terminal pro-brain natriuretic peptide (NT-proBNP) is released into the plasma predominantly from ventricular… 
2011
2011
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.
9019 Background: Currently, the NK-1 receptor antagonist (NK-1 RA) aprepitant combined with a 5-HT3 receptor antagonist (5-HT3 RA… 
2010
2010
Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine.
AIM To evaluate the impact of single and repeated doses casopitant on the pharmacokinetics of single dose midazolam and… 
Review
2009
Review
2009
Casopitant: a new warrior in the antiemetic crusade
The effective treatment of emetic complications of cancer therapies has remained a challenging task for cancer patients and their… 
2009
2009
Cardiac Safety Data for Casopitant, a Neurokinin-1 Receptor Antagonist, Given with Anthracycline.
Objectives: The NK-1 receptor antagonist casopitant is a promising agent for the prevention of chemotherapy-related and… 
2008
2008
Effect of casopitant, a novel neurokinin -1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of…
20587 Background: In clinical studies, casopitant is a dose- and duration-dependent inhibitor of CYP3A4, as well as a moderate… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)